Caricamento...
MRD evaluation of AML in clinical practice: are we there yet?
MRD technologies increase our ability to measure response in acute myeloid leukemia (AML) beyond the limitations of morphology. When applied in clinical trials, molecular and immunophenotypic MRD assays have improved prognostic precision, providing a strong rationale for their use to guide treatment...
Salvato in:
| Pubblicato in: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Hematology
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913462/ https://ncbi.nlm.nih.gov/pubmed/31808906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000060 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|